Related Experiment Videos
Carbamazepine versus phenobarbital for partial onset seizures in children
Insights
Phenobarbital (PB) and carbamazepine (CBZ) showed no significant differences in cognitive or behavioral effects for children with new partial onset seizures. Carbamazepine caused more systemic issues, with a non-significant trend towards better seizure control.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Partial onset seizures are common in children.
- Phenobarbital and carbamazepine are frequently used antiepileptic drugs.
Purpose of the Study:
- To compare the efficacy and safety of phenobarbital versus carbamazepine in children with newly diagnosed partial onset seizures.
- To evaluate the impact of these drugs on cognitive function and behavior.
Main Methods:
- Randomized, double-blind study involving 39 children.
- Children received either phenobarbital or carbamazepine.
- Psychometric and behavioral assessments were conducted at baseline and at 6- and 12-month follow-ups.
Main Results:
- No significant differences were observed between phenobarbital and carbamazepine regarding cognitive or behavioral outcomes.
- Carbamazepine was associated with a higher incidence of systemic problems.
- A trend towards improved seizure control with carbamazepine was noted but did not reach statistical significance.
Conclusions:
- Both phenobarbital and carbamazepine appear to have comparable effects on cognitive and behavioral status in children with newly diagnosed partial onset seizures.
- Carbamazepine may present a higher risk of systemic side effects.
- Further research is needed to confirm seizure control efficacy and optimize treatment strategies.
Abstract:
Thirty-nine children were treated with either phenobarbital (PB) or carbamazepine (CBZ) for newly diagnosed partial onset seizures. Drug selection was randomized in 33 subjects. Parents and the psychologist evaluating the child were blind to drug identity. Psychometric and behavioral evaluations were done at intake and at 6- and 12-month follow-ups. There were no significant differences between drugs in effect on behavior or cognitive function. CBZ caused more systemic problems. There was a trend toward better seizure control with CBZ, but this was not statistically significant. Although individual children in each group had changes in behavior or cognitive status, neither group changed significantly, in either acute or chronic follow-up.